Category: Unified Patent Court
-
UPC to become “default choice” for patent litigation across many industries, says Umicore Head of IP
The UPC is a “hugely important development in the global IP landscape” and is proving to be an “excellent forum” for patent disputes, Umicore’s head of IP, Sean Alexander, told ip fray in an interview at the third annual IP Dealmakers Europe. Umicore has filed one infringement case in the UPC and is considering filing…
-
UPC Roundup (1 week): Mannheim LD separates Ericsson patent cases; Munich LD narrows use of confidential licensing materials; strict scheduling standards
This is a summary of developments in and around the Unified Patent Court (UPC) in the calendar week of May 11, 2026.
-
UPC infringement filings shift beyond Germany as German-based divisions’ share drops to 50% in April 2026
New data suggests a gradual shift in infringement filings away from Germany-based divisions. While Germany remains dominant, its share of infringement actions fell to 50 percent in April 2026, reflecting increasing claimant confidence in non-German UPC venues.
-
Via licensor Philips settles Qi dispute with Belkin; Renault takes patent license from Broadcom
Based on decisions by the UPC to close cases, two significant SEP disputes have apparently been settled: Philips-Belkin (a win for Via in all likelihood) and Broadcom-Renault.
-
CureVac expands Spikevax patent fight to UPC with new action against Moderna in Hague LD
In a significant patent battle for mRNA vaccines, CureVac has now joined others in suing in the UPC, taking the dispute with Moderna, which started in Delaware, to the Hague LD.
-
UPC proposes terms for ZTE-Samsung cross-license: $640M for 5 years, $730M for 6; consistent with Chongqing, Munich; otherwise PMAC mediation
The Unified Patent Court’s Mannheim Local Division makes two settlement proposals with different contract terms and alternatively suggests mediation by the UPC’s Patent Mediation and Arbitration Centre.
-
10x settles with Curio, immediately goes on to sue Element Biosciences over next-generation sequencing patents
In the next-generation sequencing space, 10x Genomics has settled its litigation with Curio Biosciences, just before filing a new patent infringement lawsuit against Element Biosciences in Delaware.
-
UPC Roundup (1 week): CoA says generic reference is not leave to appeal; CD Milan revokes remdesivir-related patent; and more
This is a summary of developments in and around the Unified Patent Court (UPC) in the calendar week of May 4, 2026.
-
Samsung requested €295M ($350M) security for enforcement of Germany-wide patent injunction against its phones and tablets
Samsung defended itself in that case (barring a successful appeal), so there will be no need for enforcement security. But the collateral demand is interesting in light of a German injunction ZTE obtained against Samsung last week.
-
Nissan settles patent dispute with Broadcom
Broadcom is still embroiled in litigation with Renault (which is under enormous settlement pressure as an injunction is being enforced) and Hyundai.